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Case
We report a case of a 65-year-old female with an anaphy-
lactic type reaction during a graded oral celecoxib chal-
lenge. She was previously using NSAIDS and Celebrex
(celecoxib) for analgesia in 2005. However, due to the
side effect profile of COX2 inhibitors, Celebrex was dis-
continued. The patient’s primary analgesic was ibuprofen.
Upon reintroduction of Celebrex, the patient developed
urticaria after the second dose and urticaria with angioe-
dema after the third dose. When the patient presented to
the allergy clinic, it was felt that the urticaria and angioe-
dema were secondary to ibuprofen. Because she had a
negative crude prick skin test to Celebrex, an oral chal-
lenge to Celebrex was done. One hour after the 200 mg
cumulative challenge, the patient was asymptomatic and
an additional 200 mg was given. Twenty minutes later
the patient developed facial flushing, angioedema,
respiratory distress and hypotension, with her blood
pressure dropping to 78/53 mmHg from a baseline of
120/80 mmHg. The patient was treated with epinephrine
0.1 mg subcutaneously, without recovery. After 5 and
15 minutes additional 0.2 mg subcutaneous epinephrine
injections were administered. She was also treated with
Reactine 20mg and prednisone 50mg. The patient was
stabilized within thirty minutes.
The patient was able to tolerate ibuprofen and sulfo-
namide antibiotics without any side effects. She was also
taking hydrochlorothiazide on a daily basis for hyperten-
sion. She does not have any previously documented
allergies or adverse reactions to medications.
Discussion
Our patient had an anaphylactic type reaction to celecoxib.
Most patients that have a reaction to celecoxib are thought
to have a hypersensitivity to the sulfonamide moiety.
There are two types of sulfonamide moieties in
medications. Antibiotics that contain sulfonamide have
the arylamine moiety, whereas other medications such
as hydrochlorothiazide contain the nonarylamine
moiety. Usually patients with a hypersensitivity to the
arylamine sulfonamide can tolerate medications with
the nonarylamine sulfonamide, as they do not typically
cross react. In our case, the patient tolerated sulfona-
mide antibiotics (arylamine) and hydrochlorothiazide
(nonarylamine) meaning that she is not reacting to
either of the sulfonamide groups, but rather another
component of Celebrex.
Conclusion
Anaphylaxis to Celebrex, although rare, has been reported
in the literature. We report a case of anaphylactic reaction
to Celebrex in a patient that tolerated both arylamines and
nonarylamines sulfonamides, suggesting that our patient
has a hypersensitivity to a different component of
Celebrex. This requires further study and demonstrates
necessary caution when challenging with COX2 inhibitors.
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